-
2024-519322-20-00
5
2025-07-21
metastatic colorectal cancer
-
2024-516633-12-00
5
2025-06-30
Locally advanced/ metastatic gastroesophageal junction and gastric can
-
2024-513111-27-00
5
2025-06-26
Psoriatic Arthritis
-
2024-512696-12-00
4
2025-06-24
BCR-ABL1+ Chronic Myeloid Leukemia
-
2024-517545-13-00
11
2025-06-04
Neovascular Age-Related Macular Degeneration
-
2024-517101-87-00
5
2025-05-26
Intestinal Malabsorption
-
2023-509547-27-00
5
2025-05-22
Geographic Atrophy Secondary to Age-Related Macular Degeneration
-
2024-513959-33-00
4
2025-05-13
Asthma
-
2023-510155-37-00
5
2025-05-08
Hypomethylating agent (HMA) naive myelodysplastic syndromes
Myelodyspl
-
2024-516009-22-00
5
2025-04-30
myelodysplastic neoplasms/syndromes (MDS)
-
2024-516030-35-00
5
2025-04-30
Multiple myeloma
-
2024-514465-18-00
9
2025-04-23
Advanced or Metastatic Non-Squamous NSCLC
-
2024-517284-23-00
5
2025-04-23
Active Psoriatic Arthritis
-
2023-506206-38-00
4
2025-04-09
Diffuse Large B-cells non-Hodgkin Lymphoma
-
2023-504904-26-00
5
2025-04-07
Progressive Pulmonary Fibrosis
-
2024-514643-28-00
4
2025-03-25
Arrhythmogenic Cardiomyopathy (ACM)
-
2023-505311-20-01
5
2025-03-21
Metastatic Non-Small Cell Lung Cancer
-
2024-515566-13-00
5
2025-03-19
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2023-510292-65-00
5
2025-02-25
chronic graft-versus-host disease
-
2023-509853-29-00
10
2025-02-24
amyotrophic lateral sclerosis
-
2024-519310-31-00
4
2025-01-27
Anemia due to MDS with del5q with IPSS-R very low, low, or intermediat
-
2023-510323-30-00
5
2025-01-24
First-line treatment of recurrent or metastatic PD-L1+ head and neck s
-
2023-506675-96-00
5
2025-01-23
Heart Failure
-
2024-514724-16-01
4
2025-01-14
Acute Myeloid Leukemia